Adventures in peptides and science with students! the joys of research.

Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 6.80

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A (1982) 4.85

4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A (1980) 2.80

Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA (1991) 1.93

Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem (1995) 1.92

alpha-Melanotropin: the minimal active sequence in the frog skin bioassay. J Med Chem (1987) 1.75

Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem (1989) 1.54

Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. Biochem J (1990) 1.51

Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors. Angew Chem Int Ed Engl (2008) 1.36

Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br J Pharmacol (2010) 1.30

Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci (2003) 1.24

Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol (1998) 1.23

Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. Proc Natl Acad Sci U S A (1996) 1.23

Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem (2007) 1.21

Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin Ther Targets (2003) 1.19

Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-D-phenylalanine]-alpha-melanotropin. Science (1981) 1.10

Development of potent μ and δ opioid agonists with high lipophilicity. J Med Chem (2010) 1.08

Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors. Bioorg Med Chem Lett (2006) 0.92

Topographical modification of melanotropin peptide analogues with beta-methyltryptophan isomers at position 9 leads to differential potencies and prolonged biological activities. J Med Chem (1995) 0.89

Melanotropic peptides for therapeutic and cosmetic tanning of the skin. Ann N Y Acad Sci (1993) 0.82

De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor. J Med Chem (1998) 0.82